Treatment with Cisplatin and Etoposide Chemotherapy in Patient with Metastatic Breast Cancer.
- Author:
Mi KIM
1
;
Jin sun LEE
Author Information
- Publication Type:Original Article
- Keywords: Breast neoplasms; Chemotherapy; Cisplatin; Etoposide; Metastasis
- MeSH: Breast Neoplasms*; Breast*; Cisplatin*; Disease-Free Survival; Drug Therapy*; Etoposide*; Humans; Incidence; Injections, Intravenous; Neoplasm Metastasis; Treatment Failure
- From: Journal of Breast Disease 2017;5(2):39-45
- CountryRepublic of Korea
- Language:Korean
- Abstract: PURPOSE: Both the incidence of breast cancer as well as, the number of patients with metastatic breast cancer has increased. Taxane and anthracycline chemotherapy is known to be effective in metastatic breast cancer; however, the subsequent treatment option when such treatment fails remains unestablished. The aim of the present study was to analyze the effect and response of cisplatin and etoposide treatment along with the predictive factor for patients who failed taxane and anthracycline chemotherapy for metastatic breast cancer. METHODS: Forty-three patients with breast cancer whose regimen was changed to cisplatin and etoposide chemotherapy from taxane and anthracycline chemotherapy owing to treatment failure were included in this study. The chemotherapy regimen consisted of intravenous injection of 100 mg/m2 etoposide and 70 mg/m2 cisplatin on day 1 and then intravenous injection of 100 mg/m2 etoposide on days 2 and 3. This cisplatin and etoposide chemotherapy was repeated at 3 week intervals, and patients were assessed after the 2nd or 3rd cycle of therapy to evaluate the tumor response. RESULTS: The average cycle and progression-free survival of cisplatin and etoposide chemotherapy were 4±3.1 (range, 1–16) and 12±14.2 weeks (range, 0–60 weeks), respectively. The average overall survival was 44±33.9 months (range, 11–149 months). The treatment response group consisted of 23 patients (53.5%) who continuously received cisplatin and etoposide chemotherapy for over four cycles, while the non-response group consisted of 20 patients (46.5%) who underwent three or fewer cycles of chemotherapy. Patients with excellent response to cisplatin and etoposide chemotherapy also showed good response to taxane and anthracycline chemotherapy (p=0.011). CONCLUSION: In patients who show good response to taxane and anthracycline chemotherapy, cisplatin and etoposide chemotherapy is also expected to have a positive result.
